References
- World Health Organization. Hepatitis C (Newsroom/fact sheets). Available from http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed February 27, 2020.
- World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C infection - July 2018. Available from https://www.who.int/publications/i/item/9789241550345. Accessed March 19, 2022.
- World Health Organization. Global hepatitis report, 2017. Available from http://www.who.int/hepatitis/publications/global-hepatitisreport2017/en/. Accessed February 27, 2020.
- Jeong SH, Jang ES, Choi HY, Kim KA, Chung WK, Ki M. Current status of hepatitis C virus infection and countermeasures in South Korea. Epidemiol Health 2017;39:e2017017. https://doi.org/10.4178/epih.e2017017
- Ahmad T, Yin P, Saffitz J, et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology 2015;62(2):409-16. https://doi.org/10.1002/hep.27488
- Yang YM, Choi EJ. Efficacy and safety outcomes of sofosbuvirbased treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials. Ther Clin Risk Manag 2017;13:477-97. https://doi.org/10.2147/TCRM.S134818
- Ahmed AM, Doheim MF, Mattar OM, et al. Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis. J Med Virol 2018;90(5):907-18. https://doi.org/10.1002/jmv.24947
- Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-Pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 2018;378(4):354-69. https://doi.org/10.1056/NEJMoa1702417
- Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV Infection. N Engl J Med 2017;376(22):2134-46. https://doi.org/10.1056/NEJMoa1613512
- Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV Infection: 2 phase 3 randomized trials. Gastroenterology 2017;153(1):113-22. https://doi.org/10.1053/j.gastro.2017.03.047
- Poordad F, Felizarta F, Asatryan A, et al. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 2017;66(2):389-97. https://doi.org/10.1002/hep.29081
- Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol 2016;22(1):76-139. https://doi.org/10.3350/cmh.2016.22.1.76
- Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24(3):169-229. https://doi.org/10.3350/cmh.2018.1004
- Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33(2):464-70. https://doi.org/10.1053/jhep.2001.22172
- Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604-12. https://doi.org/10.7326/0003-4819-150-9-200905050-00006
- Yang Y, Wu FP, Wang WJ, et al. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China. World J Gastroenterol 2019;25(44):6551-60. https://doi.org/10.3748/wjg.v25.i44.6551
- Miotto N, Mendes LC, Zanaga LP, et al. All-oral direct antiviral treatment for hepatitis C chronic infection in a real-life cohort: The role of cirrhosis and comorbidities in treatment response. PLoS One 2018;13(7):e0199941. https://doi.org/10.1371/journal.pone.0199941
- Chen P, Ma A, Liu Q. Cost-effectiveness of elbasvir/grazoprevir versus daclatasvir plus asunaprevir in patients with chronic hepatitis C virus genotype 1b infection in China. Clin Drug Investig 2018;38(11):1031-9. https://doi.org/10.1007/s40261-018-0702-9
- Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-77. https://doi.org/10.2147/DDDT.S172512
- Gayam V, Hossain MR, Khalid M, et al. Real-world clinical efficacy and tolerability of direct-acting antivirals in hepatitis C monoinfection compared to hepatitis C/human immunodeficiency virus coinfection in a community care setting. Gut Liver 2018;12(6):694-703. https://doi.org/10.5009/gnl18004
- Darvishian M, Wong S, Binka M, et al. Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies. J Viral Hepat 2020;27(3):243-60. https://doi.org/10.1111/jvh.13228
- Yamamoto H, Ikesue H, Ikemura M, et al. Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis. J Pharm Health Care Sci 2018;4(1):1-8. https://doi.org/10.1186/s40780-017-0097-4
- Levin JM, Dabirshahsahebi S, Bauer M, Huckins E. Retrospective analysis of hepatitis C infected patients treated through an integrated care model. World J Gastroenterol 2016;22(38):8558-67. https://doi.org/10.3748/wjg.v22.i38.8558
- Costa VD, Pellegrini P, Rotman V, et al. Resistance mutations A30K and Y93N associated with treatment failure with sofosbuvir and daclatasvir for hepatitis C virus infection non-responder patients: case reports. Viruses 2019;11(11):1004. https://doi.org/10.3390/v11111004
- Yu ML, Hung CH, Huang YH, et al. Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. J Formos Med Assoc 2019;118(2):556-64. https://doi.org/10.1016/j.jfma.2018.11.007
- Olea Jr. A, Grochowski J, Luetkemeyer AF, Robb V, Saberi P. Role of a clinical pharmacist as part of a multidisciplinary care team in the treatment of HCV in patients living with HIV/HCV coinfection. Integr Pharm Res Pract 2018;7:105-11. https://doi.org/10.2147/IPRP.S169282
- Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65(4):727-33. https://doi.org/10.1016/j.jhep.2016.06.015
- Ravi S, Axley P, Jones D, et al. Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis. Gastroenterology 2017;152(4):911-2. https://doi.org/10.1053/j.gastro.2016.12.021
- Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65(4):719-26. https://doi.org/10.1016/j.jhep.2016.04.008
- Su F, Ioannou GN. Hepatocellular carcinoma risk after direct-acting antiviral therapy. Clin Liver Dis (Hoboken) 2019;13(1):6-12. https://doi.org/10.1002/cld.781